Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history.
Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial OperationsLibby brings strong team building, growth, and sales operations and systems skills to Sanuwave after a career of growing startups into mid- and large-sized companies.
Sanuwave Health Selected for Inclusion in Russell 2000® IndexEDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (
NASDAQ: SNWV), a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 2025 Russell indexes reconstitution, the Company’s inclusion in the Russell 2000® Index. This will be effective after the U.S. market opens on June 30. In addition to the Russell 2000® Index, the Company is also expected to be included in the broader Russell 3000® Index and in the Russell Microcap® Index.
Sanuwave Health Appoints Greg Bazar to Board of DirectorsBazar brings decades of experience in engineering, computer science and cyber security, AI, and business intelligence over a career of building successful companies
Sanuwave Announces Q1 FY2025 Financial ResultsQ1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial ResultsEDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (
NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, May 9, 2025, at 8:30 AM (ET) to present its Q1 2025 financial results.
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history.
SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial ResultsQ4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company.
SANUWAVE Will Host a Conference Call on March 21, 2025 at 8:30 AM (ET) to Present Q4 and Full Year 2024 Financial Results
SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (
NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, March 21, 2025, at 8:30 AM (ET) to present its Q4 and Full Year 2024 financial results.
